DE69616333D1 - Thip zur behandlung von schlafstörungen - Google Patents

Thip zur behandlung von schlafstörungen

Info

Publication number
DE69616333D1
DE69616333D1 DE69616333T DE69616333T DE69616333D1 DE 69616333 D1 DE69616333 D1 DE 69616333D1 DE 69616333 T DE69616333 T DE 69616333T DE 69616333 T DE69616333 T DE 69616333T DE 69616333 D1 DE69616333 D1 DE 69616333D1
Authority
DE
Germany
Prior art keywords
sleep disorders
thip
treating sleep
sub
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69616333T
Other languages
English (en)
Other versions
DE69616333T2 (de
Inventor
Marike Lancel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69616333(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to DE69616333T priority Critical patent/DE69616333T2/de
Application granted granted Critical
Publication of DE69616333D1 publication Critical patent/DE69616333D1/de
Publication of DE69616333T2 publication Critical patent/DE69616333T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69616333T 1995-07-13 1996-07-10 Thip zur behandlung von schlafstörungen Expired - Fee Related DE69616333T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69616333T DE69616333T2 (de) 1995-07-13 1996-07-10 Thip zur behandlung von schlafstörungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel
PCT/EP1996/003018 WO1997002813A1 (en) 1995-07-13 1996-07-10 Non-allosteric gabaa agonists for treating sleep disorders
DE69616333T DE69616333T2 (de) 1995-07-13 1996-07-10 Thip zur behandlung von schlafstörungen

Publications (2)

Publication Number Publication Date
DE69616333D1 true DE69616333D1 (de) 2001-11-29
DE69616333T2 DE69616333T2 (de) 2002-07-04

Family

ID=7766768

Family Applications (4)

Application Number Title Priority Date Filing Date
DE19525598A Expired - Fee Related DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel
DE69616333T Expired - Fee Related DE69616333T2 (de) 1995-07-13 1996-07-10 Thip zur behandlung von schlafstörungen
DE69616375T Expired - Fee Related DE69616375T2 (de) 1995-07-13 1996-07-10 Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE69616376T Expired - Fee Related DE69616376T2 (de) 1995-07-13 1996-07-10 Verwendung von Tiagabin zur Behandlung von Schlafstörungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19525598A Expired - Fee Related DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69616375T Expired - Fee Related DE69616375T2 (de) 1995-07-13 1996-07-10 Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE69616376T Expired - Fee Related DE69616376T2 (de) 1995-07-13 1996-07-10 Verwendung von Tiagabin zur Behandlung von Schlafstörungen

Country Status (12)

Country Link
US (1) US5929065A (de)
EP (3) EP0840601B1 (de)
JP (3) JP3754705B2 (de)
AT (3) ATE207352T1 (de)
AU (1) AU723954B2 (de)
CA (1) CA2226582C (de)
CL (1) CL2003002785A1 (de)
DE (4) DE19525598C2 (de)
DK (3) DK0867184T3 (de)
ES (3) ES2166111T3 (de)
PT (3) PT840601E (de)
WO (1) WO1997002813A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
EP0991409B1 (de) * 1997-08-01 2002-01-30 ELAN CORPORATION, Plc Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
WO2002000209A2 (en) * 2000-06-26 2002-01-03 Warner-Lambert Company Gabapentin analogues for sleep disorders
AU2002338855B2 (en) * 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
ES2341004T3 (es) 2003-06-25 2010-06-14 H. Lundbeck A/S Gaboxadol para tratar la depresion y otros trastornos afectivos.
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005023256A1 (en) * 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
ES2515092T3 (es) * 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
WO2005079851A2 (en) * 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
EP1734956A1 (de) * 2004-04-02 2006-12-27 H.Lundbeck A/S Behandlung von atemwegsstörungen mit gaboxadol
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
US20150352085A1 (en) * 2014-06-06 2015-12-10 Ovid Therapeutics Inc. Methods of increasing tonic inhibition and treating secondary insomnia
WO2016150953A1 (en) 2015-03-24 2016-09-29 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2019028234A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
CA3120856A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
JP2022512247A (ja) 2018-12-14 2022-02-02 ファツィオ，ライモンド 格闘技のトレーニングデバイス
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
KR20220114572A (ko) 2019-12-18 2022-08-17 오비드 테라퓨틱스 인크. 1p36 결실 증후군의 치료적 치료를 위한 가복사돌
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CA3228780A1 (en) * 2021-08-11 2023-02-16 Brian TANCOWNY Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
PT867178E (pt) 2002-04-29
EP0840601B1 (de) 2001-10-24
DE69616376T2 (de) 2002-06-27
AU723954B2 (en) 2000-09-07
PT840601E (pt) 2002-04-29
EP0867178A1 (de) 1998-09-30
EP0867184B1 (de) 2001-10-24
PT867184E (pt) 2002-04-29
DE69616333T2 (de) 2002-07-04
JP2005047925A (ja) 2005-02-24
US5929065A (en) 1999-07-27
EP0840601A1 (de) 1998-05-13
EP0867184A1 (de) 1998-09-30
JP2009057382A (ja) 2009-03-19
DE69616375T2 (de) 2002-07-11
WO1997002813A1 (en) 1997-01-30
DK0867184T3 (da) 2002-02-18
DK0867178T3 (da) 2002-02-18
ATE207356T1 (de) 2001-11-15
ATE207352T1 (de) 2001-11-15
ATE207349T1 (de) 2001-11-15
CA2226582C (en) 2008-02-19
JP3754705B2 (ja) 2006-03-15
ES2166110T3 (es) 2002-04-01
EP0867178B1 (de) 2001-10-24
DE69616375D1 (de) 2001-11-29
AU6613796A (en) 1997-02-10
DE19525598A1 (de) 1997-01-16
CA2226582A1 (en) 1997-01-30
ES2165990T3 (es) 2002-04-01
CL2003002785A1 (es) 2005-04-08
ES2166111T3 (es) 2002-04-01
DE69616376D1 (de) 2001-11-29
DK0840601T3 (da) 2002-02-18
JPH11509194A (ja) 1999-08-17
DE19525598C2 (de) 1997-09-25

Similar Documents

Publication Publication Date Title
DE69616333D1 (de) Thip zur behandlung von schlafstörungen
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69939651D1 (de) Behandlung hyperproliferativer erkrankungen
DE69629238D1 (de) Vorrichtung zur Behandlung des Atemstillstands im Schlaf durch Elektrostimulation
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69614739T2 (de) Pflaster zur Behandlung von Pflanzen
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE306269T1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
SE9501773D0 (sv) New use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee